Biopharma PEG Scientific Inc.

🔬 Monodispersed PEG linkers for precise bioconjugation ✔ Defined MW & structure ✔ Strong solubility & low immunogenicity ✔ Flexible groups: Azide, Amine, NHS, Maleimide, BOC/FMOC, etc g–kg scale | GMP available biochempeg.com/product/541/ #PEG #ADC #Bioconjugation

The ADC breakout was just the beginning. 🚀 With Enhertu nearing $5B in sales, the industry is officially pivoting to the XDC (Everything-Drug Conjugate) era. From PDCs to RDCs and AOCs, the "modular" drug revolution is here. 🧬 biochempeg.com/article/1464.h…

🌸 Multi-Arm PEG for PEGylation Why Multi-arm PEG ✔ Larger hydrodynamic size ✔ Improved steric shielding ✔ Longer circulation time Multiarm PEGs are explored in PEGylated therapeutics like IZERVAY, Skytrofa, YORVIPATH,etc Explore our Multi-Arm PEG: biochempeg.com/product/546/

Happy New Year! Thank you to all our clients and partners for a great year. Wishing you success and growth in the year ahead. #happynewyear #NewYear2026

🦃 This Thanksgiving, we just want to say thank you to everyone who’s been working with us this year. To keep your projects moving: • >95% purity, low impurities • From gram to kg, at a fair price 🔗 biochempeg.com 📩 sales@biochempeg.com #Thanksgiving #PEG #ADC

📊 ADC Market Update H1 2025 Global sales hit ~$8B (FY 2025 est. >$16B) Top sellers: Enhertu, Padcev, Kadcyla, Polivy, Adcetris, Trodelvy 41 ADCs in Phase III across 50+ targets 🚀 Rising stars: HER3, B7-H3, CLDN18.2, ROR1 👉 Full article: biochempeg.com/article/447.ht… #ADC #Oncology

BETAMI–DANBLOCK trial: Beta-blockers are recommended for myocardial infarction and reduced left ventricular ejection fraction, but potential benefits for preserved or mildly reduced ejection fraction are unclear. Research findings are summarized in a new Quick Take video. nej.md/41DqahQ

3 of 19 approved ADCs use PEG linkers for stability & precision: 🔹 Trodelvy® 🔹 Zynlonta® 🔹 Jiataile® (China) Biopharma PEG delivers >95% purity PEG linkers (impurities <0.5%) to power ADC innovation. biochempeg.com/adc-conjugation

Breaking! The FDA has approved Wegovy #semaglutide to treat #MASH in adults with moderate-to-advanced fibrosis. fda.gov/drugs/news-eve…

🚀 PROTACs are moving fast: 40+ candidates in trials, targeting AR, ER, BTK & more. 3 in Phase 3: 🔹 ARV-471 (FDA NDA, PDUFA June 2026) 🔹 BMS-986365 🔹 BGB-16673 biochempeg.com/article/434.ht… A new drug class may be just around the corner. 👀 #PROTAC #Oncology #DrugDiscovery

🔹 Y-shape-PEG-NHS (2-Arm PEG-NHS) enables efficient amine-reactive conjugation for proteins, peptides & hydrogels. 💡 Ideal for tissue engineering & controlled drug release. 👉 From lab to commercial scale: sales@biochempeg.com #PEGylation #Biotech #DrugDelivery #Hydrogels

Just revealed at #ACS2025: BMS-986238, a macrocyclic PD-L1 inhibitor with a PEG linker + C18 fatty acid for long half-life & oral potential. Biopharma PEG supports such advances with custom PEGs for next-gen therapeutics. 🔗 biochempeg.com/article/441.ht… #PEGylation #BMS986238

Featured PEGs from Biopharma PEG! ✅ Monodispersed & Polydispersed ✅ GMP Grade ✅ From grams to 100 kg 🔗 biochempeg.com 📩 sales@biochempeg.com #PEGs #Biopharma #ADC #GMP

HER3-DXd BLA withdrawn. But at #ASCO25: ✅ Zenocutuzumab FDA-approved ✅ BL-B01D1: ORR 69.2% (EGFR ex20ins NSCLC) ✅ DB-1310: Solid early results HER3 isn't done—bispecifics and combos may lead the way. #NSCLC #HER3 #ADC #Oncology biochempeg.com/article/437.ht…

🚨 Big News! Biopharma PEG’s HZ-PEG-HZ (1K) has received FDA Type II DMF approval (No. 041864) ✅ 🔬 GMP-grade 📦 Supply: mg to 100 kg 💊 Ready to support global drug development! biochempeg.com/article/438.ht… 📩 sales@biochempeg.com #FDA #DMF #PEGylation #DrugDelivery #BiopharmaPEG

🚨 PROTAC 2025 Update! Top degraders enter Phase 3: 🔹 ARV-471 (ER+) 🔹 BMS-986365 (AR) 🔹 BGB-16673 (BTK) Targeting tough diseases with next-gen protein degradation tech. Full story 👉 biochempeg.com/article/434.ht… #PROTAC #Oncology #Biotech #ARV471 #BMS986365 #BGB16673

🚀 Dual-payload ADCs = the next big leap in cancer therapy! 🎯 Two payloads, one antibody = more power, less resistance. 🔥 KH815 becomes the first to enter clinical trials. biochempeg.com/article/432.ht… #ADC #CancerResearch #Oncology #Biotech #KH815 #DualPayloadADC #AACR2025

🚀 PEGylated lipids boost stability & circulation in mRNA vaccines, siRNA, & anti-cancer drugs! Their structure affects immune response & drug efficacy—a game-changer in #DrugDelivery. 💡 Discover Biopharma PEG’s high-quality PEG lipids today! 🔗 biochempeg.com/article/429.ht… #LNP

🚀 The #ADC market has surpassed $10B in sales! In 2024: 💥 Enhertu: $3.75B 💥 Kadcyla: $2.32B 💥 Padcev: $1.59B 💥 Adcetris: $1.91B 💥 Trodelvy: $1.31B (+24% from 2023) 17 ADC drugs are now approved worldwide! 🌍 🔗 Learn More: biochempeg.com/article/427.ht… #Biotech #CancerTherapy

🚨 FDA APPROVES Datroway (datopotamab deruxtecan) for HR-positive, HER2-negative breast cancer! 🎉 The 13th #ADC approval offering new hope for patients. Thanks to AstraZeneca & Daiichi Sankyo for this major milestone! biochempeg.com/article/424.ht… #FDAApproval #BreastCancer